INT55924

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.07
First Reported 1994
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 3
Total Number 3
Disease Relevance 2.26
Pain Relevance 1.80

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
sciatic nerves 1
IGKV2-30 (Homo sapiens)
Pain Link Frequency Relevance Heat
Neuritis 5 100.00 Very High Very High Very High
Sciatic nerve 1 100.00 Very High Very High Very High
metalloproteinase 1 100.00 Very High Very High Very High
Demyelination 1 99.48 Very High Very High Very High
Inflammation 4 99.20 Very High Very High Very High
MU agonist 5 99.12 Very High Very High Very High
agonist 6 96.32 Very High Very High Very High
Enkephalin 2 84.60 Quite High
Peripheral nervous system 1 83.00 Quite High
opioid receptor 3 75.00 Quite High
Disease Link Frequency Relevance Heat
Experimental Autoimmune Neuritis 5 100.00 Very High Very High Very High
Demyelinating Disease 3 99.48 Very High Very High Very High
INFLAMMATION 4 99.20 Very High Very High Very High
Endometriosis (extended) 1 98.40 Very High Very High Very High
Bordatella Infection 1 97.52 Very High Very High Very High
Adrenal Cancer 137 97.44 Very High Very High Very High
Spontaneous Abortion 3 97.12 Very High Very High Very High
Immunization 1 96.04 Very High Very High Very High
Paraparesis 1 94.20 High High
Polyradiculoneuropathy 1 86.16 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
After 24 hr of chronic administration of PLO17 (50 nM to 10 microM), a concentration-dependent loss of the ability of mu opioid agonists PLO17 and DAMGO, but not the delta opioid agonists DPDPE, nor alpha-2 adrenergic agonist UK-14304 (5-Bromo-N-(4,5,-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine) to inhibit adenylate cyclase activity was observed.
Negative_regulation (loss) of PLO17 associated with mu agonist and agonist
1) Confidence 0.07 Published 1994 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8035314 Disease Relevance 0.24 Pain Relevance 0.98
In addition, in this setting maximum suppression of 17-OHP and P4 could potentially allow maximum endometrial proliferation and improve implantation.
Negative_regulation (suppression) of 17-OHP associated with endometriosis (extended)
2) Confidence 0.00 Published 2010 Journal International Journal of Pediatric Endocrinology Section Body Doc Link PMC2910408 Disease Relevance 0.79 Pain Relevance 0.03
T cell, B cell, and macrophage infiltration, inflammatory demyelination, and local expression of interleukine-17 and matrix metalloproteinase-9 in sciatic nerves of EAN rats were significantly decreased by AUY954 treatment.
Negative_regulation (decreased) of interleukine-17 in sciatic nerves associated with demyelination, inflammation, metalloproteinase, sciatic nerve and neuritis
3) Confidence 0.00 Published 2009 Journal J. Neuroimmunol. Section Abstract Doc Link 19804913 Disease Relevance 1.23 Pain Relevance 0.80

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox